Transplanting Tissue: Safety on the Public Radar Screen
This article was originally published in Start Up
Blood safety has been on the public radar screen for more than a decade, and the focus of vast amounts of financial and human resources. But the infectious disease risks associated with tissue transplants are only now receiving widespread attention because of the troubles of CryoLife Inc. While the publicity and lack of government oversight may frighten people in the near-term, it also provides opportunities for companies to make changes that improve tissue safety.
You may also be interested in...
With AIDS and HCV under control, companies large and small are looking to protect the blood supply from a range of known and as yet unknown pathogens, which pose potential threats. Near-term attention is focusing on emerging pathogen inactivation technologies, which are moving closer to the clinic, even as questions linger about their cost effectiveness and toxicity.
Orthopedic Implants. Osteoimplant offers both standard and custom, specialty orthopedic implants including hip and shoulder implants, and trauma products, including wires, pins, plates and splints.
Towa’s US-based Breckenridge is aiming for exclusivity with its generic version of Amgen’s Kyprolis – developed with partner Natco Pharma – after obtaining one of the first approvals for several strengths of the treatment for relapsed or refractory multiple myeloma.